Abstract #286: Linagliptin (LINA) as Add-On to Empagliflozin (EMPA) and Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM): Two 24-Week Randomized, Doubleblind, Double-Dummy, Parallel-Group Trials – Study Design | Publicación